Regeneron Showcases Cancer Care Advances at ESMO 2026
Regeneron presented late-breaking Phase 3 C-POST data on Libtayo in high-risk cutaneous squamous cell carcinoma and a Phase 2 analysis exploring Libtayo's potential in neoadjuvant treatment.
Regeneron presented late-breaking Phase 3 C-POST data on Libtayo in high-risk cutaneous squamous cell carcinoma and a Phase 2 analysis exploring Libtayo's potential in neoadjuvant treatment.